Dr. Thomas Sager received his MSc degree from the University of Copenhagen, where he also received his PhD in neuroscience. Dr. Sager has worked for several years in the pharmaceutical industry with particular focus on CNS disorders. Since 1999, Dr. Sager has been working at H. Lundbeck where he is Principal Scientist. Dr. Sager´s research interests are focused on in vivo neuropharmacology ranging from early target identification studies to late stage pre-clinical pharmacological evaluation of emerging therapeutic targets, primarily within Parkinson's disease.